The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells.
Dan Zhao
No relevant relationships to disclose
Sudhandra Sundaram
No relevant relationships to disclose
Hiroaki Wakimoto
No relevant relationships to disclose
William T. Curry
No relevant relationships to disclose
Daniel P. Cahill
No relevant relationships to disclose
Tracy Batchelor
Consultant or Advisory Role - Kirin Pharmaceuticals; Merck; Novartis; Proximagen; Roche
Honoraria - Educational Concepts Group; Imedex; Oakstone Medical Publishing; Research To Pratice; Robert Michael Educational Institute LLC; UpToDate
Research Funding - AstraZeneca; Millennium; Pfizer
Other Remuneration - Advance Medical; Champions Biotechnology
Keith Flaherty
No relevant relationships to disclose
Joshua Allen
Employment or Leadership Position - Oncoceutics
Consultant or Advisory Role - Oncoceutics
Stock Ownership - Oncoceutics
Other Remuneration - Oncoceutics
Andrew S. Chi
No relevant relationships to disclose